ANP (Atrial Natriuretic Peptide) vs PEG-MGF
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →PEG-MGF
PEG-MGF (PEGylated Mechano Growth Factor) is a variant of IGF-1 that is produced in response to muscle damage. PEGylation extends its half-life from minutes to several hours, making it practical for use.
Full details →Side-by-Side Comparison
| Aspect | ANP (Atrial Natriuretic Peptide) | PEG-MGF |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 400 mcg–1.2 mg |
| Frequency | 1x daily | Less than daily |
| Cycle Length | 1–4 weeks | 4–6 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. | Activates muscle satellite cells (stem cells) and promotes their fusion to existing muscle fibers for repair and growth. MGF is produced naturally in response to mechanical stress on muscles. |
| Typical Dosage | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. | Research protocols typically use 200-400mcg injected into targeted muscle groups 2-3 times weekly, usually post-workout. |
| Administration | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. | Intramuscular injection, ideally into muscles trained that day. Best administered post-workout when satellite cell activation is relevant. |
| Side Effects | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. | Injection site soreness, potential hypoglycemia, and localized swelling. Generally well-tolerated. |
| Best For |
What They Have in Common
ANP (Atrial Natriuretic Peptide), PEG-MGF are both commonly used for:
Key Differences
Unique to PEG-MGF:
Which Has Stronger Evidence?
| Goal | ANP (Atrial Natriuretic Peptide) | PEG-MGF |
|---|---|---|
| Recovery & Healing | medium | medium |
Key Studies
ANP (Atrial Natriuretic Peptide)
- Atrial natriuretic peptide (ANP) modulates stress-induced autophagy in endothelial cells.
Biochimica et biophysica acta. Molecular cell research, 2025
- C-atrial natriuretic peptide (ANP)(4-23) attenuates renal fibrosis in deoxycorticosterone-acetate-salt hypertensive mice.
Experimental cell research, 2023
- Novel ANP (Atrial Natriuretic Peptide)-Based Therapy for Hypertension: The Promising Role of a Disease Mechanism Targeted Approach.
Hypertension (Dallas, Tex. : 1979), 2021
Ready to Learn More?
Looking for trusted sources?